Dr. Aleksander Słusarczyk presented the clinical case of a 75-year-old woman who presented with a two-month history of hematuria. Her medical history was notable for diabetes, prior myocardial ...

National survey of more than 1,100 bladder cancer patients finds nearly 80% report fear of recurrence, rising above 90% among patients under ...

Dr. Matthew Galsky participated in the Case-based panel discussion Beyond platinum: Evolving frontlines in mUC and discussed where ADCs fit in the sequencing. Dr. Galsky began by emphasizing the rapid ...

Adding LAG-3 or TIGIT ICIs to enfortumab vedotin + pembrolizumab did not improve efficacy in pts with locally advanced or metastatic carcinoma ...

Aidixi combined with toripalimab significantly improved progression-free and overall survival in HER2-expressing urothelial carcinoma, regardless of cisplatin eligibility or HER2 expression status.

A prospective, multicenter phase 2 trial evaluated the safety of neoadjuvant radiation plus immunotherapy before radical cystectomy for bladder cancer.

A new review was published in Volume 16 of Oncotarget on June 17, 2025, titled "Optimizing enfortumab vedotin plus pembrolizumab therapy." First authors Elias Antoine Karam of the Gustave Roussy and ...

Enfortumab vedotin plus pembrolizumab was associated with improvements in response, disease control, and survival when compared to chemotherapy. Results of a meta-analysis suggest that enfortumab ...

Cisplatin-based combination chemotherapy remains the standard of care for locally advanced or metastatic urothelial cancer (la/mUC); however, toxicity is substantial, responses are rarely durable, and ...

Induction Yervoy (ipilimumab) plus Opdivo (nivolumab) followed by consolidative chemoradiotherapy demonstrated bladder ...

Urothelium is the term for the mucous membrane that lines the urinary tract. This includes the renal pelvis, ureter, urinary bladder and the upper part of the urethra. In the vast majority of cases, ...